NDAINTRAVENOUSSOLUTION
Approved
Jul 2008
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
4
Data completeness
3/8 — Basic
EOVIST (gadoxetate disodium) by Bayer is field. First approved in 2008.
Drug data last refreshed 14h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
EOVIST (gadoxetate disodium) is an intravenous gadolinium-based contrast agent used for hepatobiliary MRI imaging. It functions as a magnetic resonance imaging agent that alters water proton relaxation rates, with selective hepatocyte uptake that enhances liver tissue visualization. This small-molecule contrast agent enables improved detection and characterization of liver lesions and biliary dysfunction.
LOE Approaching
As a mature contrast agent approaching loss of exclusivity with moderate competitive pressure (30/100), the brand team is likely focused on retention and managed decline rather than growth expansion.
Mechanism of Action
field. The magnetic moment alters the relaxation rates of water protons in its vicinity in the body, leading to an increase in signal intensity (brightness) of tissues. Gadoxetate is selectively taken up by hepatocytes, resulting in increased signal intensity in liver tissue.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (4)
Magnetic Resonance Imaging of the Liver in Children 0-2 Months of Age With an Intravenous Injection of Eovist/Primovist Which is a Contrast Agent
Started Feb 2015
1 enrolled
Magnetic Resonance Imaging
MRI of the Liver With Eovist
Started Aug 2010
4 enrolled
Hepatocellular Carcinoma
Liver MRI With Primovist/Eovist in Pediatric Subjects Who Are Suspected or Have Focal Liver Lesions.
Started Dec 2009
52 enrolled
Liver NeoplasmsAdenomaCarcinoma+1 more
Primovist / Eovist in Renally Impaired Patients
Started May 2009
357 enrolled
Contrast Media
Worked on EOVIST at Bayer? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.